Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease.
The complete workflow is depicted in Fig. 1. To investigate the association between NPIs and AD, we initially conducted preprocessing and integration of biomedical triples...
Compared with other neurologic problems, few films have been dedicated to degenerative dementia. To our knowledge, this is the first systematic review about the...